UK markets closed

Nyxoah S.A. (NYXH)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
21.05-0.38 (-1.79%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close21.43
Open21.47
Bid21.00 x 1200
Ask21.89 x 900
Day's range21.05 - 21.88
52-week range19.05 - 37.00
Volume268
Avg. volume6,943
Market cap542.427M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.12
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est42.19
  • Globe Newswire

    Nyxoah Provides General Corporate Update

    Nyxoah Provides General Corporate Update Transformational 2021 positions Nyxoah for further clinical, regulatory, and commercial milestones in 2022 Mont-Saint-Guibert, Belgium – January 10, 2022, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implant

  • Globe Newswire

    Information on the total number of voting rights and shares

    REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), November 26, 2021, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the belowinformation following the exercise of subscription rights and the issue of new shares. Share capital: EUR 4,427,369.69 Total number of securities carrying voting rights: 25,772,3

  • Globe Newswire

    Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference

    Nyxoah Announces Participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference Mont-Saint-Guibert, Belgium. – November 12, 2021, 10:30 pm CET / 4:30 pm ET - Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Piper Sandler 33rd Annual V